Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix to Sell $35.1M in Common Stock, Inks $50M Loan Agreement

NEW YORK — Biodesix said on Thursday that it has priced a public offering of 30.5 million shares of its stock at $1.15 apiece for expected gross proceeds of $35.1 million.

The offering is expected to close on Nov. 21 and includes a 30-day option granted to the underwriters of the offering for the purchase of an additional 4.575 million shares at the same price per share. William Blair is the sole bookrunning manager for the offering.

Biodesix also said on Wednesday that it has signed a $50 million loan agreement with Perceptive Advisors, with $30 million available upfront and the remainder available in two $10 million tranches.

Proceeds of the deal, which is contingent on Biodesix raising at least $30 million through the sale of its securities, will be used to repay existing debt, as well as for working capital and general corporate purposes such as the expansion of commercialization activities around the company's five Medicare-reimbursed lung cancer diagnostics.

Upon receipt of the initial loan money, Biodesix will grant Perceptive Advisors warrants to purchase up to 5 million shares of its common stock, with warrants exercisable into 3 million shares issued upon receipt of the initial $30 million.

Earlier this month, the Boulder, Colorado-based firm reported ending the third quarter with $15.2 million in cash and cash equivalents.

During early morning trading on the Nasdaq, shares of Biodesix were up nearly 3 percent at $1.18.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.